site stats

Dyne therapeutics logo png

WebApr 3, 2024 · Catherine Stehman-Breen, M.D., Dyne’s chief medical officer, held senior leadership roles at Amgen and Regeneron Pharmaceuticals, and most recently served … WebOct 4, 2024 · Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, visits ...

Dyne Therapeutics NasdaqGS:DYN Stock Report - Simply Wall St

WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … WebThe 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Dyne Therapeutics Inc 50-day moving average is $12.61. smart builder solutions https://ashishbommina.com

$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks …

WebDyne Therapeutics Information. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in ... WebFeb 9, 2024 · Glassdoor gives you an inside look at what it's like to work at Dyne Therapeutics, including salaries, reviews, office photos, and more. This is the Dyne … WebMay 16, 2024 · DYNE-101 is designed to enable targeted delivery to muscle tissue and address the genetic basis of the disease. The new data being presented during ASGCT … smart builders asheville

Investors & Media Dyne Therapeutics

Category:Dyne Therapeutics - Funding, Financials, Valuation & Investors

Tags:Dyne therapeutics logo png

Dyne therapeutics logo png

Dyne Therapeutics Inc - Company Profile and News

WebDyne Therapeutics Inc. 1560 Trapelo Road. Waltham, Massachusetts 02451. Phone 1 781 786-8230. Industry Biotechnology. Sector Health Care/Life Sciences. WebSep 17, 2024 · Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, raised $233 million by offering 12.3 million shares at $19, above the range of $16 to $18.

Dyne therapeutics logo png

Did you know?

WebJan 20, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular ...

WebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised … WebMay 14, 2024 · In January 2024, Dyne reported data showing that two doses (2 x 10 mg/kg) of its lead DM1 candidate resulted in significant toxic human nuclear DMPK knockdown at 14 days. New data being presented ...

WebFeb 9, 2024 · 1 to 50 Employees. Founded: 2024. Type: Company - Public (DYN) Industry: Biotech & Pharmaceuticals. Revenue: Less than $1 million (USD) Competitors: Unknown. WebAug 10, 2024 · Dyne Therapeutics today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital. Contacts Stephanie Simon Ten Bridge Communications (617 ...

WebDyne Therapeutics is a biotechnology company which offers targeted therapies for patients with cardiac diseases, and serious and smooth muscle diseases. The Company …

WebFind company research, competitor information, contact details & financial data for Dyne Therapeutics, Inc. of Waltham, MA. Get the latest business insights from Dun & … smart builders incWebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1). hill street carparkWebMar 24, 2024 · Dyne Therapeutics Inc Registered Shs's market capitalization is $642.40 M by 56.34 M shares outstanding. Dyne Therapeutics Stock Snapshot. ... Logos Global … smart builders suppliesWebJan 20, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy … hill street chippy stoke on trentWebSep 6, 2024 · Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy August … hill street blues tv charactersWebMay 7, 2024 · A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at March 2024, Dyne Therapeutics had cash of US$483m and no debt ... hill street cafe food networkWebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically … Mar 10, 2024: 8-K: Report of unscheduled material events or corporate event. … The Investor Relations website contains information about Dyne Therapeutics, … Amy Reilly. Senior Vice President, Corporate Communications & Investor … hill street cafe la canada california